Article

Mechanisms of drug resistance to vascular endothelial growth factor (VEGF) inhibitors.

Department of Medicine, Division of Hematology and Oncology, George Washington University Medical Center, 2150 Pennsylvania Avenue NW, Washington, DC 20037, USA.
Anti-cancer agents in medicinal chemistry 10/2010; 10(8):593-600. pp.593-600
Source: PubMed

ABSTRACT Angiogenesis inhibitors have a major role in the treatment of varying cancers today. While originally thought to be independent of resistance, increasing data suggests varying mechanisms that bring about drug resistance, either intrinsically or through adaptation. The role of vascular endothelial growth factor single nucleotide polymorphisms (VEGF SNPs) in terms of therapeutic response and toxicity has increasingly been recognized, as well as its potential for contributing to drug resistance. This review will focus on theories, preclinical models, and clinical trials that help elucidate the mechanisms of resistance and clinical response to angiogenesis inhibitors.

0 0
 · 
0 Bookmarks
 · 
18 Views
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

angiogenesis inhibitors
 
clinical response
 
independent
 
intrinsically
 
major role
 
preclinical models
 
therapeutic response
 
toxicity
 
varying cancers
 
varying mechanisms
 
vascular endothelial growth factor single nucleotide polymorphisms
 
VEGF SNPs